The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pflanz, S.
Right arrow Articles by Müller-Newen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pflanz, S.
Right arrow Articles by Müller-Newen, G.
The Journal of Immunology, 2000, 165: 7042-7049.
Copyright © 2000 by The American Association of Immunologists

Two Different Epitopes of the Signal Transducer gp130 Sequentially Cooperate on IL-6-Induced Receptor Activation1

Stefan Pflanz, Ingo Kurth, Joachim Grötzinger, Peter C. Heinrich and Gerhard Müller-Newen2

Institut für Biochemie, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cytokines are key mediators for the regulation of hemopoiesis and the coordination of immune responses. They exert their various functions through activation of specific cell surface receptors, thereby initiating intracellular signal transduction cascades which lead to defined cellular responses. As the common signal-transducing receptor subunit of at least seven different cytokines, gp130 is an important member of the family of hemopoietic cytokine receptors which are characterized by the presence of at least one cytokine-binding module. Mutants of gp130 that either lack the Ig-like domain D1 ({Delta}D1) or contain a distinct mutation (F191E) within the cytokine-binding module have been shown to be severely impaired with respect to IL-6 induced signal transduction. After cotransfection of COS-7 cells with a combination of both inactive gp130 mutants, signal transduction in response to IL-6 is restored. Whereas cells transfected with {Delta}D1 do not bind IL-6/sIL-6R complexes, cells transfected with the F191E mutant bind IL-6/sIL-6R with low affinity. Combination of {Delta}D1 and F191E, however, leads to high-affinity ligand binding. These data suggest that two different gp130 epitopes, one on each receptor chain, sequentially cooperate in asymmetrical binding of IL-6/IL-6R in a tetrameric signaling complex. On the basis of our data, a model for the mechanism of IL-6-induced gp130 activation is proposed.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Cytokines are important intercellular mediators in the regulation of immune responses, hemopoiesis, fertility, and the acute phase reaction. They bind to specific cell surface receptors on their target cells and thereby induce receptor oligomerization. This event triggers juxtaposition of the cytoplasmic parts of the respective receptors and initiates the intracellular signal transduction cascade, which involves phosphorylation of diverse signaling proteins and transcription factors (1). Cytokine receptors are usually classified according to structural attributes. The predominant class 1 cytokine receptors are characterized by the presence of at least one cytokine-binding module (CBM)3 in their extracellular region. The CBM comprises two fibronectin type III-like domains, the N terminal of which contains four conserved cysteine residues, while the C-terminal domain contains a WSXWS motif (2). This type of cytokine receptor is activated by four-helix bundle cytokines which provide several epitopes to oligomerize their respective receptor subunits. Class 2 cytokine receptors share structural features with class 1 receptors but show a different pattern of cysteine residues and lack the characteristic WSXWS sequence (3).

gp130 belongs to the class 1 cytokine receptors. Its extracellular part has been predicted to consist of an N-terminal Ig-like domain (D1) followed by a CBM (D2 + D3) and three additional fibronectin type III-like domains (4) (see Fig. 1Go). This receptor is activated by the family of IL-6 type cytokines, which besides IL-6 comprises IL-11, ciliary neurotrophic factor (CNTF), leukemia-inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1 (5), and the recently described B cell-stimulating factor-3/neurotrophin-1 (6). IL-6 and IL-11 enforce the formation of a gp130 homodimer to trigger signal transduction, whereas the other family members require heterodimerization of gp130 with LIFR. OSM alternatively can initiate signal transduction by enforcing heterodimerization of gp130 with OSMRß. Whereas the latter four cytokines of the IL-6 family are able to interact directly with their signal-transducing receptor subunits, IL-6, IL-11, and CNTF must bind to their specific {alpha} receptors (IL-6R, IL-11R, CNTFR) first (5). These {alpha} receptors do not contribute to signal transduction but must bind their respective cytokines as a prerequisite for recruitment of the signal-transducing receptor subunits, because neither IL-6 nor IL-11 nor CNTF alone is able to efficiently engage its signal transducers. All three {alpha} receptors can be functionally replaced by the soluble variants, which consist of only the respective extracellular parts.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 1. Schematic representation of the gp130 constructs used in this study. The six predicted extracellular protein domains of gp130, each containing ~100 amino acids, are symbolized as ellipses, the Ig-like domain (D1) as a filled ellipse. The location of F191E is marked by a black circle. Conserved cysteines in the gp130 CBM are marked by black lines. The WSXWS motif is shown by a black bar. Boxes 1/2 represent conserved motifs required for binding of Jak kinases. YDKPH is a sequence motif from the IFN-{gamma} receptor that in its tyrosine-phosphorylated form recruits STAT1 (D, domain; TM, transmembrane domain; Fc, C-terminal constant domains of human IgG1 heavy chain including cysteine residues required for covalent dimerization).

 
IL-6/IL-6R-induced homodimerization of gp130 leads to activation of the intracellularly associated tyrosine kinases of the Janus (Jak) family, Jak1, Jak2, and Tyk2. These kinases in turn phosphorylate tyrosine residues in the cytoplasmic part of the signal transducer gp130 (7, 8), which thereby become docking sites for STAT transcription factors (9, 10). gp130 predominantly activates Jak1 and STAT3. Subsequently, bound STAT factors become phosphorylated, dimerize, and translocate to the nucleus to activate transcription of diverse target genes.

Two crucial binding epitopes of gp130 are involved in gp130 activation by IL-6/IL-6R: one epitope involves the Ig-like domain; and the other epitope is located in the CBM (11, 12, 13). Disturbances introduced to any of these epitopes, such as deletion of D1 or mutation of critical amino acid residues in the CBM (e.g., F191), resulted in a gp130 devoid of biological activity in response to IL-6 or IL-11 stimulation. In this study, we asked whether both epitopes must be present on both receptor subunits in the context of a gp130 homodimer to allow IL-6-induced signal transduction to occur. Our results demonstrate an intercatenar complementary cooperativity between the two epitopes, which must be engaged in a defined sequential order to trigger the cytoplasmic signal transduction cascade. Moreover, our data reveal an alternative stoichiometry for cell surface IL-6/IL-6R/gp130 ternary complexes compared with those complexes described for the soluble components (14, 15). A model for the IL-6 induced activation mechanism of gp130 is presented that might also be applicable to closely related ligand/receptor systems.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Enzymes, proteins, Abs, chemicals, and cell culture

Enzymes were purchased from Boehringer Mannheim (Mannheim, Germany), protein A-Sepharose from Pharmacia (Freiburg, Germany). DMEM and antibiotics were obtained from Life Technologies (Eggenstein, Germany), and FCS from Seromed (Munich, Germany). Radiochemicals were purchased from Amersham International (Amersham, U.K.). Recombinant human IL-6 was expressed in Escherichia coli, refolded, and purified as described by Arcone et al. (16). Soluble IL-6R was prepared as described previously (17). The monoclonal gp130 Ab B-P4 was generated as described elsewhere (18). All other Abs were purchased from Dako (Hamburg, Germany). PBS buffer contained 200 mM NaCl, 2.5 mM KCl, 8 mM Na2HPO4, and 1.5 mM KH2PO4. Simian monkey kidney cells (COS-7) were cultured in DMEM supplemented with 10% (v/v) FCS, streptomycin (100 µg/ml), and penicillin (60 µg/ml).

Plasmid construction and transfection of cells

Generation of mutants gp130F191E and gp130{Delta}D1 as well as Fc and {gamma} constructs has been described previously (13, 19). To obtain both gp130 mutants in the context of a WT cytoplasmic tail, the extracellular parts of the respective {gamma} constructs were cloned into pSVL/gp130 via XhoI/EcoRI digestion. COS-7 cells were transiently transfected applying the DEAE-dextran method. It is important to emphasize that in all transfections equal total amounts of receptor-encoding plasmid-DNA were used; in case of a two-plasmid transfection, the vectors encoding each individual receptor construct were used only in one-half the amount compared with single-plasmid transfection. Efficiency of transfection was analyzed by FACS.

Flow cytometry

Cells were collected, washed, and resuspended in PBS containing 5% FCS and 0.1% sodium azide (PBS-F/azide) at 4°C and subsequently incubated on ice with 1 µg/ml gp130 Ab B-P4 for 30 min. Cells were washed with cold PBS-F/azide and incubated with R-PE-conjugated anti-mouse IgG Fab fragment at a 1:50 dilution for another 30 min. Again, cells were washed with cold PBS-F/azide and then resuspended in 400 µl PBS-F/azide followed by flow cytometry analysis using a FACScalibur (Becton Dickinson).

EMSA

COS-7 cells were incubated at 37°C for 15 min in the presence of IL-6 (12.5 ng/ml)/sIL-6R (500 ng/ml) or left unstimulated. Preparations of nuclear extracts and EMSAs were performed as described (20). A double-stranded sis-inducible element (SIE) oligonucleotide derived from the c-fos promoter (m67SIE; 5'-GATCC GGGAG GGATT TACGG GAAA TGCTG-3') was used as [32P]DNA probe (21). The protein-DNA complexes were separated on a 4.5% polyacrylamide gel containing 7.5% glycerol. The electrophoresis was performed using 0.25-fold Tris-bufferered EDTA at 250 V. Intensities of radioactive bands were quantified using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

Soluble ternary complex formation assay

Soluble gp130Fc and respective mutants from supernatants of transfected COS-7 cells were incubated with 0.75 mg/ml protein A-Sepharose. After an overnight incubation at 4°C, immunoprecipitates were washed three times with TNET (20 mM Tris-HCl (pH 7.5), 140 mM NaCl, 1 mM EDTA, 0.4% Triton X-100) and incubated with 10 nM IL-6 and 40 nM sIL-6R in TNET. After 8 h, the Sepharose-bound proteins were washed three times with TNET, resuspended in Laemmli buffer, incubated at 95°C for 10 min, and separated on a 12.5% SDS-polyacrylamide gel under reducing conditions followed by electroblotting.

Binding of 125I-labeled IL-6 to transiently transfected COS-7 cells

COS-7 cells (2.5 x 104) transiently transfected with equal total amounts of gp130 expression plasmid were cultured in DMEM for 48 h post transfection and then incubated with a constant amount of sIL-6R (100 nM) in combination with varying amounts of 125I-labeled IL-6 (67,000 cpm/ng) ranging from 0.125 to 8 nM in binding medium (20 mM HEPES/0.2%BSA in DMEM). After incubation for 12 h at 4°C, supernatants were separated from the cells, the cells were washed twice with PBS, and cell-associated vs free radioactivity was measured using a gamma counter. Specific binding was obtained by subtracting the radioactivity associated with mock transfected COS-7 cells.

Reporter gene assay using transfected COS-7 cells

COS-7 cells were transiently transfected with equal total amounts of expression vectors encoding gp130 wild-type or the respective mutants, an IRF-1 promoter luciferase gene reporter construct (22), and a ß-galactosidase control vector. After 30 h, transfected cells were stimulated with IL-6 (15 ng/ml)/soluble (s) IL-6R (500 ng/ml) in serum-free medium or left unstimulated. After a further 24 h, luciferase activity was measured using the luciferase kit from Promega (Madison, WI) and normalized to ß-galactosidase activity to correct for transfection efficiency.

Immunoblotting and ECL detection

Immunoprecipitated proteins separated by SDS-PAGE were transferred to a polyvinylidene difluoride (PVDF) membrane by a semidry electroblotting procedure (23). PVDF membranes were blocked in a solution of 20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 0.1% Nonidet P-40 containing 10% BSA and probed with Ab, followed by incubation with HRP-conjugated secondary Ab. Immunoreactive proteins were detected by chemiluminescence using the ECL kit (Amersham, Little Chalfont, U.K.) following the manufacturer’s instructions.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Two different epitopes involving the Ig-like domain or the CBM of gp130 cooperate in the formation of a signal-transducing gp130 homodimer in response to IL-6

Previous studies demonstrated the importance of two distinct receptor epitopes for IL-6-induced activation of gp130: one epitope is located in the gp130-CBM; and the other involves the Ig-like domain (D1) (12, 13). Disturbances introduced to any of these two epitopes such as mutation of a critical amino acid residue in the CBM (F191) or deletion of D1 abolished gp130-mediated signal transduction after stimulation with IL-6. Thus, efficient receptor dimerization could not be achieved by gp130 molecules defective in either D1 or the CBM. In the present study, we investigated whether both critical gp130 epitopes are required in each of the two homodimer-forming gp130 receptors for efficient signal transduction.

As a first approach, a reporter gene assay was performed using a luciferase reporter gene under the control of the IRF-1 promoter. COS-7 cells were transiently transfected with equal total amounts of plasmid DNA encoding gp130 wild-type, gp130F191E (F191E), gp130{Delta}D1 ({Delta}D1), the combination of gp130F191E and gp130{Delta}D1 (F191E/{Delta}D1), or empty expression vector (Fig. 1Go, left). Transfected cells were stimulated with IL-6 (15 ng/ml)/sIL-6R (500 ng/ml) or were left unstimulated. Because COS-7 cells contain small amounts of endogenous gp130, the stimulation had to be suboptimal to minimize reporter induction in the mock transfected cells. When transfected alone, neither of the two mutants F191E and {Delta}D1 was able to significantly induce the reporter gene (Fig. 2Go). After transfection of the combination F191E/{Delta}D1, a restored reporter gene activity could be monitored. Because of the suboptimal stimulation, the overall induction of the IRF-1 promoter was weak even on transfection of gp130 wild-type (1.60 ± 0.09). Nevertheless, the differences in gene induction for control (1.02 ± 0.04), F191E (1.08 ± 0.01), and {Delta}D1 (1.06 ± 0.02) on the one hand and the combination F191E/{Delta}D1 (1.32 ± 0.06) on the other hand are significant and were reproducible in three independent experiments. Statistical significance was proved, applying Student’s t test with a probability value of {alpha} = 0.05 (data not shown).



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 2. IL-6-induced induction of the IRF-1 promoter in transiently transfected COS-7 cells. Besides a ß-galactosidase vector and a luciferase gene reporter under the control of the IRF-1 promoter, cells were transfected with equal total amounts of cDNA encoding gp130, empty expression vector as a control, F191E, {Delta}D1 or the combination F191E/{Delta}D1, respectively. Thirty hours after transfection, the cells were transferred to serum-free medium. Subsequently, cells were stimulated with suboptimal concentrations of IL-6 (15 ng/ml) in the presence of a large molar excess of sIL-6R (500 ng/ml) or were left unstimulated. After 24 h, luciferase activity was measured and normalized to ß-galactosidase activity to correct for transfection efficiency. Luciferase activity/ß-galactosidase activity was calculated for stimulated vs unstimulated cells to determine relative induction of the reporter. Error bars indicate SDs derived from three independent experiments. For mock transfected cells, the mean values of measured raw data for unstimulated vs stimulated cells derived from the three experiments are as follows: 2.17 x 106 vs 3.01 x 106 luciferase U, 463 vs 634 ß-galactosidase U, consequently 4.69 x 103 vs 4.75 x 103 luciferase activity corrected for transfection efficiency by ß-galactosidase activity.

 
To confirm these observations in the context of a rapid signaling response such as STAT activation, COS-7 cells were again transfected with the respective receptor constructs. However, to overcome STAT activation via the small amounts of endogenous gp130 present in COS-7 cells, the receptor constructs used for transfection were further mutated to contain a cytoplasmic part comprising the gp130 box1/2-sequences required for recruitment of Jak kinases followed by the exclusively and strongly STAT1-activating tyrosine motif YDKPH derived from the IFN-{gamma} receptor ({gamma} constructs, Fig. 1Go, middle) (11). A comparable cell surface expression of the receptor {gamma} constructs was observed by FACS (Fig. 3GoA), using the gp130 mAb B-P4. This mAb recognizes an epitope located in the membrane-proximal part of gp130 (24); thus, binding is not affected by either the point mutation or the deletion of D1. The comparable cell surface expression of the three proteins (gp130{gamma}, F191E{gamma}, and {Delta}D1{gamma}) indicates that the overall structure of gp130 was not affected by the mutations. Otherwise, the receptors would not be able to appear on the cell surface but as a result of partial misfolding would have been intracellularly degraded.



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 3. IL-6-induced STAT activation in transiently transfected COS-7 cells. A, COS-7 cells were transiently transfected with the expression vectors as indicated; again equal total amounts of DNA were used. Forty-eight hours after transfection, the cells were incubated with the gp130 mAb B-P4 and stained with a PE-labeled secondary Ab. Mock transfected cells served as a control. Unspecific fluorescence by the secondary Ab alone is represented by the gray peak; the transparent peaks monitor cellular fluorescence intensities after overexpression of gp130 or the respective mutants. B, Total lysates of COS-7 cells were prepared 48 h after transient transfection with the gp130{gamma} construct or the respective mutants as described in A. Mock transfected cells served as a control. Cellular proteins were separated by SDS-PAGE and electroblotted. gp130{gamma} and mutants were detected by immunostaining using the gp130 mAb B-P4 and visualized by ECL. {alpha} hgp130, anti-human gp130. C, Analysis of STAT1 activation in COS-7 cells transiently transfected with equal total amounts of cDNA encoding gp130{gamma}, a control plasmid, F191E{gamma}, {Delta}D1{gamma}, and the combination F191E{gamma}/{Delta}D1{gamma}. Forty-eight hours after transfection with the respective expression plasmids, as indicated, cells were stimulated with IL-6 (12.5 ng/ml) and sIL-6R (500 ng/ml) for 15 min (+) or were left unstimulated (-). Nuclear extracts were prepared and subsequently analyzed by EMSA; a typical autoradiograph is shown (top). Mock transfected cells served as a control. Radioactivity of STAT1-DNA complexes were analyzed using a PhosphorImager. Counts obtained from STAT1 activation were normalized relative to the maximal signal intensity obtained for gp130{gamma}. Error bars indicate SDs derived from three independent experiments (bottom).

 
In FACS analysis, the Ab B-P4 does not discriminate between the two mutants F191E{gamma} and {Delta}D1{gamma}. To verify expression of both mutants after cotransfection, cell lysates were prepared, subjected to SDS-PAGE, and analyzed by Western blotting (Fig. 3GoB). All proteins were detectable at electrophoretic mobilities corresponding to their anticipated molecular masses, demonstrating that cotransfection of F191E{gamma} and {Delta}D1{gamma} indeed led to coexpression of both mutants. {Delta}D1{gamma} shows an increased electrophoretic mobility correlating with the deletion of a 100-aa polypeptide containing two potential N-glycosylation sites.

COS-7 cells, transfected with equal total amounts of expression plasmids encoding gp130{gamma}, F191E{gamma}, {Delta}D1{gamma}, the combination F191E{gamma}/{Delta}D1{gamma}, or a control plasmid were stimulated with IL-6, and a large molar excess of sIL-6R or were left unstimulated. Nuclear extracts were prepared and analyzed by EMSA for STAT1 DNA-binding activities (Fig. 3GoC, top). Intensities of the radioactive bands corresponding to STAT1/DNA complexes were quantified using a PhosphorImager (Fig. 3GoC, bottom). Transfection of F191E{gamma} or {Delta}D1{gamma} alone did not lead to significant STAT1 activation. In each experiment, levels of STAT1, which has been activated by these two individual mutants, range within the background activation observed for the mock transfected control cells. This implies that the potential of gp130 to mediate signal transduction is severely impaired by either of the two mutations. The combination F191E{gamma}/{Delta}D1{gamma}, however, elicited about one-half the STAT1 activation mediated through gp130{gamma}. These results are in line with the previous data obtained by the reporter gene assay (see Fig. 2Go).

An epitope involving the Ig-like domain cooperates with the CBM of gp130 for efficient binding of IL-6/sIL-6R complexes

The restoration of IL-6 sensitivity by combination of two per se inactive receptor mutants pointed to a complementary involvement of two different gp130 epitopes on two receptor chains in the context of a gp130 dimer. This hypothesis was further analyzed in a coimmunoprecipitation assay, investigating the binding of IL-6/sIL-6R to soluble Fc fusion proteins of the gp130 mutants. The extracellular parts of gp130, F191E, and {Delta}D1 were fused to the Fc part of hIgG1 (Fc constructs, Fig. 1Go, right). The Fc fusion proteins are covalently dimerized via the cysteine residues responsible for the connection of the two heavy chains in an Ab. This experimental design enabled us to investigate the ligand-binding capacity of our gp130 mutants as preformed dimers in solution.

COS-7 cells were transiently transfected with equal total amounts of the three single expression plasmids sgp130Fc, sF191EFc, or s{Delta}D1Fc; the combination of sF191EFc/s{Delta}D1Fc; or a control plasmid. The soluble dimeric receptor-Fc fusion proteins can be precipitated directly from the cell supernatants using protein A-Sepharose. These primary precipitates were subsequently incubated with IL-6/sIL-6R, and a coprecipitation experiment was performed. Sepharose-associated proteins were separated by SDS-PAGE under reducing conditions, blotted, and immunodetected using Abs recognizing the Fc part of the fusion proteins and hIL-6, respectively. SDS-PAGE under nonreducing conditions retarded the Fc fusion proteins to an apparent molecular mass of >220 kDa, indicating that the soluble Fc fusions were indeed expressed as cysteine-bridged dimers (data not shown). sgp130Fc potently coprecipitated IL-6 in the presence of sIL-6R, whereas sF191EFc showed only weak coprecipitation capacity, and the deletion mutant s{Delta}D1Fc was unable to coprecipitate detectable IL-6 quantities (Fig. 4Go). This experimental design rules out the possibility that one {Delta}D1 initially binds IL-6/sIL-6R very weakly and therefore cannot survive the time span required for the second {Delta}D1 to join the complex; the {Delta}D1 mutant itself apparently is not capable of binding to IL-6/sIL-6R.



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 4. Soluble ternary complex formation assay using IL-6/sIL-6R with sgp130Fc, sF191EFc, s{Delta}D1Fc, and the combination sF191EFc/s{Delta}D1Fc in a coprecipitation experiment. COS-7 cells were transfected with equal total amounts of expression vectors encoding the three individual gp130 variants and the combination sF191EFc/s{Delta}D1Fc, respectively. Sixty hours after transfection, the Fc fusion proteins were precipitated from the cell supernatants using protein A-Sepharose. Sepharose-bound proteins were incubated with IL-6/sIL-6R as indicated. The ternary complexes formed were precipitated, separated by SDS-PAGE, and transferred to PVDF membranes. Proteins were visualized by ECL using the Abs indicated. {alpha} hgp130, anti-human gp130; {alpha} hIL-6, anti-human IL-6.

 
The amount of IL-6 that was coprecipitated by the combination of sF191EFc and s{Delta}D1Fc ranges between the amounts observed with sgp130Fc and sF191EFc. As demonstrated by the immunodetection of Fc, the sum of precipitated receptor fusion proteins in the combination sF191EFc/s{Delta}D1Fc (Fig. 4Go, top, lane 6) did at least not exceed the levels of precipitated single proteins sF191EFc and s{Delta}D1Fc (Fig. 4Go, top, lanes 4 and 5). Thus, the increase in coprecipitated IL-6 by sF191EFc/s{Delta}D1Fc cannot be attributed to higher expression levels of the combination compared with sF191EFc. Moreover, from a statistical point of view, coexpression of sF191EFc and s{Delta}D1Fc will lead to three different species of cysteine-bridged Fc dimers in the cellular supernatants: 25% (sF191EFc)2; 25% (s{Delta}D1Fc)2; and 50% dimers as sF191EFc/s{Delta}D1Fc. Therefore, the IL-6 amounts shown in lane 6 must have been coprecipitated by a significantly lower number of Fc dimers compared with lane 4, because s{Delta}D1Fc dimers were found to be completely inactive (lane 5). These results point to a remarkably increased IL-6/sIL-6R-binding capability of the combination sF191EFc/s{Delta}D1Fc compared with sF191EFc or s{Delta}D1Fc.

High affinity binding of IL-6/sIL-6R can be restored by combining F191E with {Delta}D1

Binding of IL-6/sIL-6R complexes to the mutants was further investigated using membrane-bound receptors. gp130 has been found to convert the low affinity binding between IL-6 and IL-6R into a high affinity ternary complex (4). COS-7 cells were transiently transfected with equal total amounts of plasmids encoding F191E{gamma}, {Delta}D1{gamma}, or the combination F191E{gamma}/{Delta}D1{gamma}. The {gamma} constructs were chosen because they lead to enhanced surface expression because of the lack of the gp130 dileucine motif required for efficient internalization of the receptor (25). Mock transfected cells served as a control. As described above, cell surface expression of all transfected constructs was analyzed by FACS and by Western blot analysis of total cell lysates (data not shown, but comparable with those in Fig. 3Go, A and B). The IL-6/sIL-6R-binding capacities of the two gp130 mutants and their combination during expression on the cell surface was studied by an equilibrium binding assay using radiolabeled IL-6 (125I-labeled IL-6). To saturate the initial low affinity equilibrium between IL-6 and sIL-6R, transfected cells were incubated with 125I-labeled IL-6 in the presence of a large molar excess of sIL-6R. By this means the three-components system (IL-6, sIL-6R, gp130) was reduced to two components ({IL-6/sIL-6R}, gp130), regarding the complex of IL-6/sIL-6R as an activated heterodimeric cytokine.

Scatchard analysis of the binding data is shown in Fig. 5Go. Strong overexpression of {Delta}D1 does not lead to a significant enhancement of IL-6-binding capacity because the bound radioactivity barely exceeds the radioactivity associated with mock transfected cells (the data in Fig. 5Go result from subtraction of the low levels of 125I-labeled IL-6-binding to mock transfected cells). Overexpression of F191E{gamma} leads to the formation of a huge amount of low affinity binding sites. This coincides with the low level of IL-6/sIL-6R binding by sF191EFc (Fig. 4Go). The combination of F191E{gamma} with {Delta}D1{gamma}, however, results in the formation of both low and high affinity binding sites.



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 5. Scatchard analysis of 125I-labeled IL-6 binding to transfected COS-7 cells. COS-7 cells (2.5 x 104) transfected with equal total amounts of the expression plasmids encoding F191E{gamma} ({blacktriangleup}, dotted line), {Delta}D1{gamma} ({blacksquare}), or the combination of F191E{gamma} and {Delta}D1{gamma} (•, solid line) were incubated with varying amounts (0.125–8 nM) of [125I]-IL-6 in the presence of an excess of sIL-6R (100 nM). After incubation for 12 h at 4°C, free and cell-bound radioactivity was measured. Specific binding was obtained by subtraction of the low levels of radioactivity associated with mock transfected cells. Each point of data represents the mean value of two independent experiments.

 
From the Scatchard plot the Kd of the high affinity interaction was calculated to be in the range of 350–450 pM. This value fits well with the data obtained from cells expressing gp130 endogenously (210–380 pM (26)) as well as from COS-7 cells transfected with gp130 wild type (330–650 pM (27)). The number of high affinity binding sites critically depends on transfection efficiency. From the data in Fig. 5Go, a number of ~57,000 high affinity binding sites was calculated. This is in agreement with previous observations obtained from COS-7 cells transfected with gp130 wild type (12,000–51,000 sites/cell (27)). For the low affinity interaction, quantitative evaluation of the Scatchard data is limited because for practical reasons 125I-labeled IL-6 could not be applied at near saturation concentrations. Nevertheless, the data allow a good estimation of the low affinity interaction with a Kd of 13–18 nM. Thus, the affinity is reduced by a factor of 33–45.

Taken together, the binding data are in line with the findings described above supporting the concept that two different gp130 epitopes on two receptor chains cooperate in high affinity ligand binding and activation of the signal transducer.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Initiation of cellular signal transduction via gp130 activation requires a gp130 dimer of a distinct conformation because dimerization per se was shown to be necessary but not sufficient for receptor activation (28). The appropriate dimerization is achieved by the specific interaction of gp130 with the IL-6/IL-6R complex. Recent studies applying site-directed mutagenesis as well as investigation of gp130 deletion mutants (12, 13, 29) revealed that one epitope participating in the interaction with IL-6/IL-6R involves the Ig-like domain (in the following referred to as epitope A; this epitope is lacking in the {Delta}D1 mutant) and the other is located in the CBM (referred to as epitope B; this epitope is destroyed in the F191E mutant). The data presented here show that functional homodimerization of gp130 carrying mutations in either epitope A or epitope B is not possible (Figs. 2Go and 3GoC). The combination of one epitope A-defective ({Delta}D1) with an epitope B-defective (F191E) gp130 mutant, however, restored receptor activity (Figs. 2Go and 3GoC) and led to high affinity binding of IL-6/sIL-6R (Fig. 5Go). Accordingly, epitopes A and B are both required to allow IL-6-induced activation, but one pair of complementary epitopes on two different receptor chains is sufficient to constitute an active gp130 dimer. Thus, gp130 epitopes A and B cooperate inter- but not intramolecularly on IL-6-induced receptor activation.

Site-directed mutagenesis of IL-6 led to the identification of three distinct epitopes (sites) responsible for the interaction with IL-6R (site I) and the two gp130 molecules (sites II and III) (30). Similarly positioned receptor-engaging epitopes have been described for the closely related cytokines IL-11 (31, 32) and CNTF (33), which signal via gp130/gp130 homodimers and gp130/LIFR heterodimers, respectively. The initial event in the formation of a signal transducing IL-6/IL-6R/gp130 ternary complex on the cell surface is the contact of site I of IL-6 with IL-6R, which is a prerequisite for the engagement of gp130 because neither IL-6 nor IL-6R alone have a detectable affinity for gp130. How the two gp130 molecules join the IL-6/IL-6R complex is currently not known. Previous studies demonstrated that the Ig-like domain of gp130 is not needed for LIF- as well as OSM-induced activation in the context of a gp130/LIFR heterodimer (12, 34). Instead, in these complexes the Ig-like domain of the LIFR contributes to ligand binding (35, 36). In another report, the authors altered the receptor specificity of IL-6. They created an IL-6/CNTF cytokine hybrid by transferring site III of CNTF into the IL-6 molecule (IC7), thereby switching the receptor specificity from gp130/gp130/IL-6R in IL-6 to gp130/LIFR/IL-6R in IC7 (37). Taken together, these findings suggest that site II of IL-6 engages gp130 epitope B. This implies that epitope A is involved in recognition of site III.

Destruction of epitope A by deletion of the Ig-like domain ({Delta}D1 mutant) generated a gp130 molecule that did not respond to IL-6 (Figs. 2Go and 3GoC) and that was not able to bind IL-6/sIL-6R via its functional epitope B (Figs. 4Go and 5Go), whereas destruction of epitope B (F191E mutant) by site-directed mutagenesis generated a gp130 that was biologically inactive (Figs. 2Go and 3GoC) but retained residual binding activity to IL-6/sIL-6R via its functional epitope A (Figs. 4Go and 5Go). Therefore, we conclude that the interaction of IL-6 site III with gp130 epitope A is a prerequisite for interaction between site II and gp130 epitope B, eventually constituting a nonsymmetrical IL-6/IL-6R/gp130 ternary complex which is capable of initiating signal transduction. A model for IL-6-induced activation of gp130 by sequential engagement of the three receptor chains IL-6R (via site I), first gp130 (via site III/epitope A), and the second gp130 (via site II/epitope B) is shown in Fig. 6Go. We assume that epitope A might form contacts between site III and parts of the IL-6R as well, because IL-6 alone does not show a detectable affinity to gp130. Of course, we cannot exclude that conformational changes of site III that are possibly induced by binding of IL-6R to site I could account for this effect. However, the IL-6-induced signal transduction via gp130 seems to be a defined sequential three-step process, in which each step is a prerequisite for the subsequent events.



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 6. Schematic presentation of gp130 recruitment by IL-6/sIL-6R complexes. After binding of sIL-6R to site I of IL-6, the binary complex recruits epitope A of gp130 (containing D1) to site III of IL-6. This low affinity ternary complex is stabilized by binding of a second gp130 via epitope B (the gp130 CBM) to site II of IL-6 leading to the onset of the cytoplasmic signal transduction cascade (arrow).

 
Thus far, the structure of the growth hormone/growth hormone receptor complex was a paradigm for cytokine receptor complex assembly (38). In this complex, as well as in the more recently solved structure of the erythropoietin-erythropoietin receptor complex (39), sites I and II of the cytokine bind to identical epitopes of the two receptors, thereby forming the active receptor homodimer. Our findings demonstrate that within the family of class I cytokine receptors the mode of ligand recognition differs significantly, depending on the ectodomain architecture of the receptor and the binding site topology of the cytokine.

The question of the stoichiometry for IL-6/IL-6R/gp130 ternary complexes has long been subject to discussion (40). By using soluble receptor proteins, two groups have provided experimental evidence for a hexameric complex consisting of two molecules of each IL-6, sIL-6R, and sgp130 (14, 15). The data led to the proposal of two models for the architecture of the (IL-6/sIL-6R/sgp130)2 ternary complex (14, 30). Apart from differences in minor details, both models postulate contacts between IL-6 site I to the respective sIL-6R and, more importantly, demand two topologically separated contact epitopes on each sgp130: one engaging site II of one IL-6; and a second providing contacts to site III of the other IL-6. Thus, four epitopes on two sgp130 provide a double bridging of the two separate IL-6/sIL-6R units thereby assembling a hexameric complex. Alternatively, on the basis of structural considerations, a model for a tetrameric ternary complex consisting of one IL-6, one IL-6R, and two gp130 has been suggested (41). This model postulates three contacts between a single IL-6 and its receptors: IL-6 site I with IL-6R; site II with the CBM of the first gp130; and site III with the second gp130, each receptor contacting IL-6 only once. Unlike the postulate for the soluble hexameric ternary complexes, our data suggest that there does not necessarily exist a requirement for four intact gp130 epitopes with respect to IL-6-induced gp130 activation on the cell surface. We were able to show that epitope A on one gp130 and epitope B on another gp130 are sufficient to initiate IL-6 induced signal transduction. From this point of view, at least for low concentrations of IL-6/sIL-6R, the formation of a hexameric ternary complex on the cell surface seems unlikely. Because in the tetrameric complex each gp130 molecule provides a free binding site, in the presence of high IL-6 doses the formation of higher order complexes cannot be excluded (40).

Regarding our experiments investigating gp130 activation on cells, the levels of cellular responses initiated through the F191E or {Delta}D1 mutant range within the background response observed for control cells (0%), whereas gp130 gave the 100% response under the respective experimental conditions. The combination F191E/{Delta}D1 did significantly restore the cellular response but did not reach a level comparable to that of gp130 wild type. The stimulation via the combination F191E/{Delta}D1 amounts to ~50% (see Figs. 2Go and 3GoC). Provided that the receptor mutants are surface expressed in comparable amounts, this finding cannot be explained by assuming diffusible receptor monomers on the plasma membrane: After the complex of IL-6/IL-6R has been caught by epitope A of gp130, the intermediate low affinity ternary complex would be completed by association of a second gp130 providing the intact epitope B ({Delta}D1), leading to a 100% response.

Studies on the gp130/OSMR heterodimer (42) and more recent investigations on erythropoietin receptor homodimerization (43) suggest that cytokine receptors may appear as preformed dimers on the cell surface. On ligand binding, these receptor dimers switch from an inactive to an active conformation. If gp130 is predimerized in an inactive conformation independently of the ligand, from a statistical point of view four different dimers are conceivable regarding the combination of gp130 epitopes, A/A, B/B, A/B, and B/A. The former two combinations were shown to be biologically inactive, the latter two combinations are biologically active but represent only one-half of the total receptor population, which limits the expected response to 50%.

It remains to be shown whether a preformed gp130 dimer actually exists on the cell surface. In any case, the understanding not only of ligand-receptor interactions but also of receptor activation mechanisms provides a rational basis for drug design to pharmacologically interfere with the earliest event of signal transduction.


   Acknowledgments
 
We thank Andreas Timmermann, Heike Herrmanns, and Drs. Fred Schaper, Lutz Graeve, and Serge Haan for critical reading of the manuscript and Dr. John Wijdenes (Diaclone, France) for the supply of gp130 mAb B-P4.


   Footnotes
 
1 This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB 542) and the Fonds der Chemischen Industrie (Frankfurt a. M.). Back

2 Address correspondence and reprint requests to Dr. Gerhard Müller-Newen, Institut für Biochemie, Rheinisch-Westfälische Technische Hochschule Aachen, Pauwelsstrasse 30, D-52057, Aachen, Germany. Back

3 Abbreviations used in this paper: CBM, cytokine-binding module; CNTF, ciliary neurotrophic factor; LIF, leukemia-inhibitory factor; OSM, oncostatin M; s, soluble; Jak, Janus kinase; PBS-F/azide, PBS containing 5% FCS and 0.1% sodium azide; PVDF, polyvinylidene difluoride. Back

Received for publication May 25, 2000. Accepted for publication September 26, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Ihle, J. N.. 1995. Cytokine receptor signaling. Nature 377:591.[Medline]
  2. Bazan, J. F.. 1990. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87:6934.[Abstract/Free Full Text]
  3. Wells, J. A., A. M. de Vos. 1996. Hematopoietic receptor complexes. Annu. Rev. Biochem. 65:609.[Medline]
  4. Hibi, M., M. Murakami, M. Saito, T. Hirano, T. Taga, T. Kishimoto. 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149.[Medline]
  5. Heinrich, P. C., I. Behrmann, G. Müller-Newen, F. Schaper, L. Graeve. 1998. IL-6-type cytokine signalling through the gp130/JAK/STAT pathway. Biochem. J. 334:297.
  6. Senaldi, G., B. C. Varnum, U. Sarmiento, C. Starnes, J. Lile, S. Scully, J. Guo, G. Elliott, J. McNinch, C. L. Shaklee, et al 1999. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc. Natl. Acad. Sci. USA 96:11458.[Abstract/Free Full Text]
  7. Lütticken, C., U. M. Wegenka, J. Yuan, J. Buschmann, C. Schindler, A. Ziemiecki, A. G. Harpur, A. F. Wilks, K. Yasukawa, T. Taga, et al 1994. Association of transcription factor APRF and protein kinase JAK1 with the interleukin-6 signal transducer gp130. Science 263:89.[Abstract/Free Full Text]
  8. Stahl, N., T. G. Boulton, T. Farruggella, N. Y. Ip, S. Davis, B. A. Witthuhn, F. W. Quelle, O. Silvennoinen, G. Barbieri, S. Pellegrini, et al 1994. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 ß receptor components. Science 263:92.[Abstract/Free Full Text]
  9. Schmitz, J., H. Dahmen, C. Grimm, C. Gendo, G. Müller-Newen, P. C. Heinrich, F. Schaper. 2000. The cytoplasmic tyrosine motifs in full-length gp130 have different roles in IL-6 signal transduction. J. Immunol. 164:848.[Abstract/Free Full Text]
  10. Stahl, N., T. J. Farrugella, T. G. Boulton, Z. Zhong, Jr J. E. Darnell, G. D. Yancopoulos. 1995. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349.[Abstract/Free Full Text]
  11. Horsten, U., G. Müller-Newen, C. Gerhartz, A. Wollmer, J. Wijdenes, P. C. Heinrich, J. Grötzinger. 1997. Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6)/IL-6 receptor/gp130 complex. J. Biol. Chem. 272:23748.[Abstract/Free Full Text]
  12. Hammacher, A., R. T. Richardson, J. E. Layton, D. K. Smith, L. J. L. Angus, D. J. Hilton, N. A. Nicola, J. Wijdenes, R. J. Simpson. 1998. The immunoglobulin-like module of gp130 is required for signaling by interleukin-6 but not by leukemia inhibitory factor. J. Biol. Chem. 273:22701.[Abstract/Free Full Text]
  13. Kurth, I., U. Horsten, S. Pflanz, H. Dahmen, A. Küster, J. Grötzinger, P. C. Heinrich, G. Müller-Newen. 1999. Activation of the signal transducer gp130 by both interleukin-6 and interleukin-11 requires two distinct binding epitopes. J. Immunol. 162:1480.[Abstract/Free Full Text]
  14. Paonessa, G., R. Graziani, A. De Serio, R. Savino, L. Ciapponi, A. Lahm, A. L. Salvati, C. Toniatti, G. Ciliberto. 1995. Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signalling. EMBO J. 14:1942.[Medline]
  15. Ward, L. D., G. J. Howlett, G. Discolo, K. Yasukawa, A. Hamacher, R. L. Moritz, R. J. Simpson. 1994. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp130. J. Biol. Chem. 269:23286.[Abstract/Free Full Text]
  16. Arcone, R., P. Pucci, F. Zappacosta, V. Fontaine, A. Malorni, G. Marino, G. Ciliberto. 1991. Single-step purification and structural characterization of human interleukin-6 produced in Escherichia coli from a T7 RNA polymerase expression vector. Eur. J. Biochem. 198:541.[Medline]
  17. Weiergräber, O., U. Hemmann, A. Küster, G. Müller-Newen, J. Schneider, S. Rose-John, P. Kurschat, J. P. J. Brakenhoff, M. H. L. Hart, S. Stabel, P. C. Heinrich. 1995. Soluble human interleukin-6 receptor: expression in insect cells, purification and characterization. Eur. J. Biochem. 234:661.[Medline]
  18. Wijdenes, J., P. C. Heinrich, G. Müller-Newen, C. Roche, G. Zong-Jiang, C. Clement, B. Klein. 1995. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur. J. Immunol. 25:3474.[Medline]
  19. Horsten, U., H. Schmitz-Van de Leur, J. Müllberg, P. C. Heinrich, S. Rose-John. 1995. The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor. FEBS Lett. 360:43.[Medline]
  20. Wegenka, U. M., C. Lütticken, J. Buschmann, J. Yuan, F. Lottspeich, W. Müller-Esterl, C. Schindler, E. Roeb, P. C. Heinrich, F. Horn. 1994. The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transduction and transcription (Stat) factor family. Mol. Cell. Biol. 14:3186.[Abstract/Free Full Text]
  21. Wagner, B. J., T. E. Hayes, C. J. Hoban, B. H. Cochran. 1990. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J. 9:4477.[Medline]
  22. Yuan, J., U. M. Wegenka, C. Lütticken, J. Buschmann, T. Decker, C. Schindler, P. C. Heinrich, F. Horn. 1994. The signaling pathways of interleukin-6 and interferon-{gamma} converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol. Cell. Biol. 14:1657.[Abstract/Free Full Text]
  23. Kyhse-Anderson, J.. 1984. Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins form polyacrylamide to nitrocellulose. J. Biochem. Biophys. Methods 10:203.[Medline]
  24. Kurth, I., U. Horsten, S. Pflanz, A. Timmermann, A. Küster, H. Dahmen, I. Tacken, P. C. Heinrich, G. Müller-Newen. 2000. Importance of the membrane-proximal extracellular domains for activation of the signal transducer gp130. J. Immunol. 164:273.[Abstract/Free Full Text]
  25. Dittrich, E., C. R. Haft, L. Muys, P. C. Heinrich, L. Graeve. 1996. A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J. Biol. Chem. 271:5487.[Abstract/Free Full Text]
  26. Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, T. Kishimoto. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573.[Medline]
  27. Dittrich, E., S. Rose-John, C. Gerhartz, J. Müllberg, T. Stoyan, K. Yasukawa, P. C. Heinrich, L. Graeve. 1994. Identification of a region within the cytoplasmic domain of the interleukin-6 signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. J. Biol. Chem. 269:19014.[Abstract/Free Full Text]
  28. Müller-Newen, G., A. Küster, J. Wijdenes, F. Schaper, P. C. Heinrich. 2000. Studies on the IL-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies. J. Biol. Chem. 275:4579.[Abstract/Free Full Text]
  29. Moritz, R. L., L. D. Ward, G. F. Tu, L. J. Fabri, H. Ji, K. Yasukawa, R. J. Simpson. 1999. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex. Growth Factors 16:265.[Medline]
  30. Simpson, R. J., A. Hammacher, D. K. Smith, J. M. Matthews, L. D. Ward. 1997. Interleukin-6: structure-function relationships. Protein Sci. 6:929.[Medline]
  31. Barton, V. A., K. R. Hudson, J. K. Heath. 1999. Identification of three distinict receptor binding sites of murine interleukin-11. J. Biol. Chem. 274:5755.[Abstract/Free Full Text]
  32. Tacken, I., H. Dahmen, O. Boisteau, S. Minvielle, Y. Jacques, J. Grötzinger, A. Küster, U. Horsten, C. Blanc, F. Montero-Julian, et al 1999. Definition of receptor binding sites on human interleukin-11 by molecular modeling-guided mutagenesis. Eur. J. Biochem. 265:645.[Medline]
  33. Panayotatos, N., E. Radziejewska, A. Acheson, R. Somogyi, A. Thadani, W. A. Hendrickson, N. Q. McDonald. 1995. Localization of functional receptor epitopes on the structure of ciliary neurotrophic factor indicates a conserved, function-related epitope topography among helical cytokines. J. Biol. Chem. 270:14007.[Abstract/Free Full Text]
  34. Timmermann, A., S. Pflanz, J. Grötzinger, A. Küster, I. Kurth, V. Pitard, P. C. Heinrich, G. Müller-Newen. 2000. Different epitopes are required for gp130 activation by interleukin-6, oncostatin M and leukemia inhibitory factor. FEBS Lett. 468:120.[Medline]
  35. Owczarek, C. M., Y. Zhang, M. J. Layton, D. Metcalf, B. Roberts, N. A. Nicola. 1997. The unusual species cross-reactivity of the leukemia inhibitory factor receptor {alpha}-chain is determined primarily by the immunoglobulin-like domain. J. Biol. Chem. 272:23976.[Abstract/Free Full Text]
  36. Taupin, J.-C., V. Miossec, V. Pitard, F. Blanchard, S. Daburon, S. Raher, Y. Jacques, A. Godard, J.-F. Moreau. 1999. Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains. J. Biol. Chem. 274:14482.[Abstract/Free Full Text]
  37. Kallen, K. J., J. Grötzinger, E. Lelievre, P. Vollmer, D. Aasland, C. Renne, J. Müllberg, K. H. Meyer zum Büschenfelde, H. Gascan, S. Rose-John. 1999. Receptor recognition sites of cytokines are organized as exchangeable modules: transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6. J. Biol. Chem. 274:11859.[Abstract/Free Full Text]
  38. de Vos, A. M., M. Ultsch, A. A. Kossiakoff. 1992. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306.[Abstract/Free Full Text]
  39. Syed, R. S., S. W. Reid, C. Li, J. C. Cheetham, K. H. Aoki, B. Liu, H. Zhan, T. D. Osslund, A. J. Chirino, et al 1998. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395:511.[Medline]
  40. Grötzinger, J., T. Kernebeck, K.-J. Kallen, S. Rose-John. 1999. IL-6 type cytokine receptor complexes: hexamer, tetramer or both?. Biol. Chem. 380:803.[Medline]
  41. Grötzinger, J., G. Kurapkat, A. Wollmer, M. Kalai, S. Rose-John. 1997. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins 27:96.[Medline]
  42. Auguste, P., C. Guillet, M. Fourcin, C. Olivier, J. Veziers, A. Pouplard-Barthelaix, H. Gascan. 1997. Signalling of type II oncostatin M receptor. J. Biol. Chem. 272:15760.[Abstract/Free Full Text]
  43. Livnah, O., E. A. Stura, S. A. Middleton, D. L. Johnson, L. K. Jolliffe, I. A. Wilson. 1999. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283:987.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Circ. Res.Home page
D. Wang, Z. Liu, Q. Li, M. Karpurapu, V. Kundumani-Sridharan, H. Cao, N. Dronadula, F. Rizvi, A. K. Bajpai, C. Zhang, et al.
An Essential Role for gp130 in Neointima Formation Following Arterial Injury
Circ. Res., March 30, 2007; 100(6): 807 - 816.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Ancey, A. Kuster, S. Haan, A. Herrmann, P. C. Heinrich, and G. Muller-Newen
A Fusion Protein of the gp130 and Interleukin-6Ralpha Ligand-binding Domains Acts as a Potent Interleukin-6 Inhibitor
J. Biol. Chem., May 2, 2003; 278(19): 16968 - 16972.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pflanz, S.
Right arrow Articles by Müller-Newen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pflanz, S.
Right arrow Articles by Müller-Newen, G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS